TLR2 and synucleinopathy: Collectively, these results suggest that targeting TLR2 by immunotherapeutic approach decreased accumulation of neurotoxic α-synuclein aggregates and neuroinflammation, thereby ameliorating neurodegeneration and behavioral defects in an animal model of synucleinopathy.